New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
FDA Weighs Safety Standards for Psychedelic Therapies 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts 
Trump Signs Order to Cut Routine Childhood Vaccines 
Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Dubai’s connectivity remains strong in an uncertain world 
Apple Extends Qualcomm Patent Licensing Deal 
Fed Unveils Stablecoin Rules Under GENIUS Act 
Asian Currencies Mixed as Dollar Holds Near Two-Month High 
Add as a preferred source on Google
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
